NEW YORK, Jan 4 – Structural proteomics company Syrrx said Thursday it has entered into a five-year strategic alliance with the Genomics Institute of the Novartis Research Foundation (GNF).
Under the terms of the agreement, GNF has granted Syrrx an exclusive license to tools it has developed for cloning, protein expression, protein purification, and protein crystallization. Syrxx will also have access to GNF’s collection of X-ray diffraction data for use within the field of structural proteomics.
In exchange, GNF will take a minority equity position in Syrrx and a seat on the company’s board of directors.
Under the collaboration, Syrrx and GNF will co-develop automated systems to streamline the protein structure determination process. The first technologies they expect to develop include high-throughput fermentation technology, high-throughput protein purification robotics, and a high-throughput protein crystallization system.
Further terms of the alliance were not disclosed.
Syrrx plans to use the developed technologies to identify protein variants suitable for crystallization.
" This collaboration will enable our two organizations to combine our knowledge of biochemistry, computational biology, and engineering to reach goals efficiently," Wendell Wierenga, Syrrx's CEO, said in a statement.
GNF uses functional genomics and advanced technologies to enable biological discovery. The Novartis Research Institute has committed $250 million in funding to the Genomics Institute and is currently building a 180,000 square foot laboratory complex in La Jolla, Calif.